4th Quarter - Amendment

BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.

Firm
Client
Income
—
Expenses
$330,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 20, 2025 $320,000 Replaced
4th Quarter - Amendment (this page) Jul 17, 2026 $330,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Creating Hope Reauthorization Act of 2024 - H.R. 7384 Give Kids a Chance Act of 2024 - H.R. 3433 Creating Hope Reauthorization Act of 2024 - S. 4583 March-in/Bayh-Dole Act Orphan drug policies Scientific EXPERT Act of 2024 - H.R.9979 H.R.9979 - Scientific EXPERT Act of 2024 H.R.10545 - American Relief Act, 2025

LobbyistCovered position, as disclosed
MICHAEL CALVO New Rep. Taylor (NC-11) Intern, Leg. Correspondent, Leg. Asst. Rep. McHenry (NC-10) Policy Advisor Rep. Gingrey (GA-11) Senior Leg. Asst., Senior Policy Advisor, Leg. Director, Deputy Chief of Staff Rep. Hice (GA-10) Leg. Director
AMANDA MALAKOFF —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7384 (118th), H.R. 3433 (118th), H.R. 9979 (118th), S. 4583 (118th), H.R. 10545 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.